May 11, 2017, Dr. Jia Xin participated in Zhejiang forth board technology enterprises investment and financing normal roadshow-the first phase for biomedical listed enterprises
The roadshow was held by Hangzhou Economic and Technological Development Zone Administrative Committee, Zhejiang Equity Trading Center, Shenzhen Securities Information Limited together. Shao Lichun, the Party committee secretary of the Development Zone and Director of the CMC; Wang Yongfang, the Party committee member deputy director of the CMC; Bao Chuntian, deputy director of Zhejiang Province Finance Office; Jiang Xiaohua, Chairman of Zhejiang Equity Trading Center; Tang Jingsong, Shenzhen Securities Information Co., Ltd. Supervisor; and Zhou Yeliang, chairman of Zhejiang Equity Investment Industry Association have attended the roadshow. More than 100 representatives of investment institutions, banks and enterprises also have attended the roadshow.
During the roadshow, Zhejiang Equity Trading Center and Hangzhou Economic and Technological Development Zone signed a strategic cooperation agreement. Starting from the roadshow, both sides will also carry out in-depth cooperation, to settle down Zhejiang Science&Technology&Finance “Live + online” Roadshow-biomedical listed enterprises roadshow project center in Xiasha.
After the signature of the agreement, 7 breaking-through companies in biopharmaceuticals introduced their projects, followed by comments and questions from Wang Daozhen, chief investment officer of Stepholdings and Song Yongying, investment manager of Shenzhen GTJA Investment Group.
Dr. Jia Xin was the third to present, his project was The Development and Commercialization of High-level Drug Formulation/Medical Devices, including introduction to the industry, the projects, the company and investment/fundraising plan.
Today, world drug market has an annual growth rate of 4-5%, while the generic drug market grows at 10% annually. The generic pharmaceutical industry of China has lagged behind USA for 40 years, EU and Japan for 30 years, India for 10 years. Comparing with pharmaceutical industry, the medical device industry has only 20% market share in China, while that in western countries is 50%. For these reasons, China’s generic pharmaceutical industry and medical device industry have great potential.
After the roadshow, several investment institutions showed interest in Meihua Dingchang’s projects.